Non-Melanoma Skin Cancer (NMSC)
Treatment Research
Faster, non-invasive insight
for treatment research
OCT skin imaging to simplify skin assessment and treatment evaluation.
VivoSight Dx Pro delivers rapid, non-invasive OCT imaging that supports accurate BCC assessment and treatment follow-up — non-invasively.
OCT imaging is now Included in the European Consensus Guidelines for Diagnosis & Treatment of BCC, SCC & AK; and in many national Guidelines, including those of Germany, The Netherlands and Denmark.
VivoSight clinical imaging
VivoSight OCT skin imaging provides additional structural information beyond dermoscopy, supporting the non-invasive assessment of skin lesions.
Example of VivoSight OCT image of skin lesion
Designed for speed, confidence and efficiency
- Full, high‑definition non‑invasive OCT scan in just 15 seconds
- Real‑time placement of image markers during acquisition
- Real‑time 3D volume rendering for rapid lesion visualisation
- Highly cost‑effective — reducing learning curve and examination time
VivoSight Dx OCT Image of skin lesion, Image Size: 6mm x 2mm
Speed your BCC treatment research – non-invasively
See how VivoSight Dx Pro with VivoAID fits seamlessly into real-world research workflows.
The whole picture — in real time
Only VivoSight Dx Pro provides:
- >1 mm imaging depth for confident BCC characterisation
- Unrivalled 6 × 6 mm field of view for rapid visualisation of the entire lesion
- Real-time 3D OCT volume rendering with optional D-OCT vasculature imaging
- Areas of highest BCC marker density highlighted, accelerating assessment
Unrivalled field-of-view and imaging depth, compared with other OCT systems
A selection of published research on BCC using VivoSight OCT imaging:
Optical coherence tomography for diagnosing recurrent or residual basal cell carcinoma after topical treatment: A diagnostic cohort study. Wolswijk T., et.al. JADV. (2023). 89:728
Optical coherence tomography versus punch biopsy for diagnosis of basal cell carcinoma: a multicentre, randomised, non-inferiority trial. Adan, F. et.al. Lancet Oncology. (2022), 23(8) 1087
Evaluation of Optical Coherence Tomography as a Means of Identifying Earlier Stage Basal Cell Carcinomas while Reducing the Use of Diagnostic Biopsy. Markowitz, O. et al. J Clin Aesthet Dermatol. 2015, 8(10): 14
Designed for the busy research dermatologist
Purpose-built for clinical research, VivoSight Dx Pro and VivoAID deliver advanced OCT insights through an efficient, accessible workflow—reducing the complexity typically associated with research-grade imaging technologies.
Whether you are new to OCT imaging or an experienced user, VivoAID supports faster, more confident adoption. For first-time users, it shortens the learning curve. For experienced clinical researchers, the enhanced tools within VivoSight Dx Pro and VivoAID further accelerate lesion assessment and research workflows.
